Key Points
-
Neural tube closure is a highly complex process that occurs during embryogenesis. Failure of the neural tube to close can lead to neural tube defects (NTDs) such as anencephaly and spina bifida.
-
Periconceptional use of folic acid supplements prevents about a half to three-quarters of cases of NTDs. The main function of the metabolism of the vitamin folate is to transport one-carbon units, which are used in the synthesis of DNA building blocks (purines and thymidine) and for methylation of numerous compounds, including DNA, RNA, proteins and lipids.
-
A variant of the gene methylenetetrahydrofolate reductase (MTHFR) is the first genetic risk factor to be identified for NTDs. This role goes some way to explaining the prevention of NTDs by folic acid, a precursor of the natural substrate of MTHFR.
-
Knowledge of folate metabolism and the biochemical role of MTHFR has led to the development of the methylation hypothesis for NTDs, which suggests that reduced cellular methylation hampers neural tube closure.
-
If folic acid prevents NTDs through improved methylation, new therapeutic strategies, such as the administration of agents involved in donating a methyl group, for example, riboflavin, vitamin B12, methionine and choline, must be explored.
Abstract
Neural tube closure takes place during early embryogenesis and requires interactions between genetic and environmental factors. Failure of neural tube closure is a common congenital malformation that results in morbidity and mortality. A major clinical achievement has been the use of periconceptional folic acid supplements, which prevents ∼50–75% of cases of neural tube defects. However, the mechanism underlying the beneficial effects of folic acid is far from clear. Biochemical, genetic and epidemiological observations have led to the development of the methylation hypothesis, which suggests that folic acid prevents neural tube defects by stimulating cellular methylation reactions. Exploring the methylation hypothesis could direct us towards additional strategies to prevent neural tube defects.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Elwood, J. M., Little, J. & Elwood, J. H. Epidemiology and Control of Neural Tube Defects (Oxford Univ. Press, 1992).
Waitzman, N. J., Romano, P. S. & Scheffler, R. M. Estimates of the economic costs of birth defects. Inquiry 31, 188–205 (1994).
Hall, J. G. et al. Clinical, genetic, and epidemiological factors in neural tube defects. Am. J. Hum. Genet. 43, 827–837 (1988).
Copp, A. J., Greene, N. D. E. & Murdoch, J. N. The genetic basis of mammalian neurulation. Nature Rev. Genet. 4, 784–793 (2003). Excellent review of mammalian neurulation.
Detrait, E. R. et al. Human neural tube defects: developmental biology, epidemiology, and genetics. Neurotoxicol. Teratol. 27, 515–524 (2005).
Smithells, R. W., Sheppard, S. & Schorah, C. J. Vitamin deficiencies and neural tube defects. Arch. Dis. Child. 51, 944–950 (1976).
Laurence, K. M. et al. Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. BMJ 282, 1509–1511 (1981).
Smithells, R. W. et al. Apparent prevention of neural tube defects by periconceptional vitamin supplementation. Arch. Dis. Child. 56, 911–918 (1981).
Holmes-Siedle, M. et al. Vitamin supplementation and neural tube defects. Lancet 319, 275–276 (1982).
Smithells, R. W. et al. Further experience of vitamin supplementation for prevention of neural tube defect recurrences. Lancet 1, 1027–1031 (1983).
Seller, M. J. & Nevin, N. C. Periconceptional vitamin supplementation and the prevention of neural tube defects in south-east England and Northern Ireland. J. Med. Genet. 21, 325–330 (1984).
Vergel, R. G. et al. Primary prevention of neural tube defects with folic acid supplementation: Cuban experience. Prenat. Diagn. 10, 149–152 (1990).
Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group. Lancet 338, 131–137 (1991).
Czeizel, A. E. & Dudas, I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N. Engl. J. Med. 327, 1832–1835 (1992).
Mulinare, J. et al. Periconceptional use of multivitamins and the occurrence of neural tube defects. JAMA 260, 3141–3145 (1988).
Bower, C. & Stanley, F. J. Dietary folate as a risk factor for neural-tube defects: evidence from a case-control study in Western Australia. Med. J. Aust. 150, 613–619 (1989).
Milunsky, A. et al. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. JAMA 262, 2847–2852 (1989).
Werler, M. M., Shapiro, S. & Mitchell, A. A. Periconceptional folic acid exposure and risk of occurrent neural tube defects. JAMA 269, 1257–1261 (1993).
Shaw, G. M. et al. Periconceptional vitamin use, dietary folate, and the occurrence of neural tube defects. Epidemiology 6, 219–226 (1995).
Berry, R. J. et al. Prevention of neural-tube defects with folic acid in China. China–U.S. Collaborative Project for Neural Tube Defect Prevention. N. Engl. J. Med. 341, 1485–1490 (1999). Large recent study showing that oral folic acid strongly reduces the number of NTDs.
Hernandez-Diaz, S. et al. Folic acid antagonists during pregnancy and the risk of birth defects. N. Engl. J. Med. 343, 1608–1614 (2000). Reports that folate antagonists taken during pregnancy increase NTD risk.
Rothenberg, S. P. et al. Autoantibodies against folate receptors in women with a pregnancy complicated by a neural tube defect. N. Engl. J. Med. 350, 134–142 (2004).
Piedrahita, J. A. et al. Mice lacking the folic acid-binding protein are defective in early embryonic development. Nature Genet. 23, 228–232 (1999).
Finnell, R. H. et al. DNA methylation in Folbp1 knockout mice supplemented with folic acid during gestation. J. Nutrition 132 (Suppl. 8), S2457–S2461 (2002).
Spiegelstein, O. et al. Folate-regulated changes in gene expression in the anterior neural tube of folate binding protein-1 (Folbp1)-deficient murine embryos. Neurochem. Res. 29, 1105–1112 (2004).
Tang, L. S. & Finnell, R. H. Neural and orofacial defects in Folp1 knockout mice. Birth Defects Res. A Clin. Mol. Teratol. 67, 209–218 (2003).
Tang, L. S. et al. Role of Folbp1 in the regional regulation of apoptosis and cell proliferation in the developing neural tube and craniofacies. Am. J. Med. Genet. C Semin. Med. Genet. 135, 48–58 (2005).
Yates, J. R. W. et al. Is disordered folate metabolism the basis for the genetic predisposition to neural tube defects? Clin. Genet. 31, 279–287 (1987).
Kirke, P. N., Molloy, A. M. & Daly, L. E. Maternal plasma folate and vitamin B12 are independent risk factors for neural tube defects. Q. J. Med. 86, 703–708 (1993).
Van der Put, N. M. J. et al. Altered folate and vitamin B12 metabolism in families with spina bifida offspring. Q. J. Med. 90, 505–510 (1997).
Gardiki-Kouidou, P. & Seller, M. J. Amniotic fluid folate vitamin B12 and transcobalamins in neural tube defects. Clin. Genet. 33, 441–448 (1988).
Weekes, E. W. et al. Nutrient levels in amniotic fluid from women with normal and neural tube defect pregnancies. Biol. Neonate 61, 226–231 (1992).
Economides, D. L. et al. Folate and vitamin B12 concentration in maternal and fetal blood, and amniotic fluid in second trimester pregnancies complicated by neural tube defects. Br. J. Obstet. Gynaecol. 99, 23–25 (1992).
Wild, J., Schorah, C. J., Sheldon, T. A. & Smithells, R. W. Investigation of factors influencing folate status in women who have had a neural tube-affected infant. Br. J. Obstet. Gynaecol. 100, 546–549 (1993).
Luckock, M. D. et al. The methylfolate axis in neural tube defects: in vitro characterization and clinical investigation. Biochem. Med. Metab. Biol. 52, 101–114 (1994).
Institute of Medicine. Nutrition During Pregnancy 258–271 (National Academy, Washington DC, 1990).
FDA. Food standards: amendment of standards of identity for enriched grain products to require addition of folic acid. Fed. Reg. 61, 8781–8797 (1996).
Centers for Disease Control and Prevention. Knowledge and use of folic acid by women of childbearing age — United States, 1995 and 1998. Morb. Mortal. Wkly Rep. 48, 325–327 (1999).
Honein, M. A. et al. Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA 285, 2981–2986 (2001).
Williams, L. J. et al. Prevalence of spina bifida and anencephaly during the transition to mandatory folic acid fortification in the United States. Teratology 66, 33–39 (2002).
Canfield, M. A. et al. Changes in the birth prevalence of selected birth defects after grain fortification with folic acid in the United States: findings from a multi-state population-based study. Birth Defects Res. A Clin. Mol. Teratol. 73, 679–689 (2005).
Stover, P. J. Physiology of folate and vitamin B12 in health and disease. Nutr. Rev. 62, S3–S12 (2004).
van der Put, N. M. J., van Straaten, H. W. M., Trijbels, J. M. F. & Blom, H. J. Folate, homocysteine and neural tube defects: an overview. Exp. Biol. Med. 226, 243–270 (2001).
Castro, R., Rivera, I., Blom, H. J., Jakobs, C. & de Almeida, I. T. Homocysteine metabolism, hyperhomocysteinaemia and vascular disease: an overview. J. Inherit. Metab. Dis. 29, 3–20 (2006).
Steegers-Theunissen, R. P. M. et al. Maternal hyperhomocysteinemia: a risk factor for neural tube defects. Metabolism 43, 1475–1480 (1994).
Homocysteine Lowering Trialists Collaboration. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am. J. Clin. Nutr. 82, 806–812 (2005).
Jee, S. H. et al. Major gene evidence after MTHFR-segregation analysis of serum homocysteine in families of patients undergoing coronary arteriography. Hum. Genet. 111, 128–135 (2002).
Den Heijer, M. et al. Homocysteine levels — before and after methionine loading — in 51 Dutch families. Eur. J. Hum. Genet. 13, 753–762 (2005).
Blom, H. J. Mutated 5,10-methylenetetrahydrofolate reductase and moderate hyperhomocysteinaemia. Eur. J. Pediatr. 157, S131–S134 (1998).
Blom, H. J. Genetic determinants of hyperhomocysteinaemia: the roles of cystathionine β-synthase and 5,10-methylenetetrahydrofolate reductase. Eur. J. Pediatr. 159, 208–212 (2000).
Kang, S. S., Zhou, J., Wong, P. W., Kowalisyn, J. & Strokosch, G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am. J. Hum. Genet. 43, 414–421 (1988).
Engbersen, A. M. T. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am. J. Hum. Genet. 56, 142–150 (1995).
Frosst, P. et al. Identification of a candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genet. 10, 111–113 (1995). Reports that the polymorphism 677C>T leads to production of thermolabile MTHFR, and consequently is the first genetic variant to influence plasma homocysteine concentration in the population at risk for vascular disease.
van der Put, N. M. J. et al. Mutated methylenetetrahydrofolate reductase as a risk-factor for spina bifida. Lancet 346, 1070–1071 (1995). First study on the link between the MTHFR 677C>T polymorphism and NTD risk.
Ueland, P. M. & Rozen, R. (eds) MTHFR Polymorphisms and Disease 125–143 (Landes Bioscience, Georgetown, Texas, 2005).
Kluijtmans, L. A. et al. Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. Blood 101, 2483–2488 (2003).
Jacques, P. F. et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 93, 7–9 (1996).
Guenther, B. D. et al. The structure and properties of methylenetetrahydrofolate reductase from Escherichia coli suggest how folate ameliorates human hyperhomocysteinemia. Nature Struct. Biol. 6, 359–365 (1999). Elegant basic study on the MTHFR protein showing that the 677C>T polymorphism results in FAD loss, and that addition of folate prevents this loss.
McNulty, H. et al. Riboflavin lowers homocysteine in individuals homozygous for the MTHFR 677C->T polymorphism. Circulation 113, 74–80 (2006).
Boyles, A. L., Hammock, P. & Speer, M. C. Candidate gene analysis in human neural tube defects. Am. J. Med. Genet. C Semin. Med. Genet. 135, 9–23 (2005).
Finnell, R. H., Gould, A. & Spiegelstein, O. Pathobiology and genetics of neural tube defects. Epilepsia 44, 14–23 (2003).
Mitchell, L. E. et al. Spina bifida. Lancet 364, 1885–1895 (2004).
Gellekink, H. M., Den Heijer, M., Heil, S. G. & Blom, H. J. Genetic determinants of plasma total homocysteine. Sem. Vasc. Med. 5, 98–109 (2005).
Van der Linden, I. J. M., Afman, L. A., Heil, S. G. & Blom, H. J. Genetic variation in genes of folate metabolism and neural tube defect risk. Proc. Nutr. Soc. 65, 1–12 (2005).
Juriloff, D. M. & Harris, M. J. Mouse models for neural tube closure defects. Hum. Mol. Genet. 9, 993–1000 (2000).
Cabrera, R. M., Hill, D. S., Etheredge, A. J. & Finnell, R. H. Investigations into the etiology of neural tube defects. Birth Defects Res. C Embryo Today 72, 330–344 (2004).
Copp, A. J. Neurulation in the cranial region — normal and abnormal. J. Anat. 207, 623–635 (2005).
Greene, N. & Copp, A. J. Mouse models of neural tube defects: investigating preventive mechanisms. Am. J. Med. Genet. C Semin. Med. Genet. 135, 31–41 (2005).
Chen, Z. et al. Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum. Mol. Genet. 10, 433–443 (2001).
Swanson, D. A. et al. Targeted disruption of the methionine synthase gene in mice. Mol. Cell. Biol. 21, 1058–1065 (2001).
Watanabe, M. et al. Mice deficient in cystathionine β-synthase: animal models for mild and severe homocyst(e)inemia. Proc. Natl Acad. Sci. USA 92, 1585–1589 (1995).
Scriver, C. R. et al. (eds) The Metabolic and Molecular Bases of Inherited Disease 8th edn Vol. 2 2007–2056 (McGraw Hill, New York, 2001).
Scriver, C. R. et al. (eds) The Metabolic and Molecular Bases of Inherited Disease 8th edn Vol. 3 3897–3934 (McGraw Hill, New York, 2001).
Harris, M. J. & Juriloff, D. M. Maternal diet alters exencephaly frequency in SELH/Bc strain mouse embryos. Birth Defects Res. A Clin. Mol. Teratol. 73, 532–540 (2005).
van Straaten, H. W. & Copp, A. J. Curly tail: a 50-year history of the mouse spina bifida model. J. Med. Genet. 31, 383–387 (1994).
Bagley, P. J. & Selhub, J. A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc. Natl Acad. Sci. USA 95, 13217–13220 (1998).
Smith, D. E., Kok, R. M., Teerlink, T., Jakobs, C. & Smulders, Y. M. Quantitative determination of erythrocyte folate vitamer distribution by liquid chromatography–tandem mass spectrometry. Clin. Chem. Lab. Med. 44, 450–459 (2006).
Friso, S. et al. A common mutation in the 5,10-methyl-enetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc. Natl Acad. Sci. USA 9, 5606–5611 (2002).
Castro, R. et al. 5,10-methylenetetrahydrofolate reductase (MTHFR) 677C>T and 1298A>C mutations are associated with DNA hypomethylation. J. Med. Genet. 41, 454–458 (2004).
Okano, M., Bell, D. W., Haber, D. A. & Li, E. DNA methyltransferase Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99, 247–257 (1999).
Afman, L. A., Blom, H. J., van der Put, N. M. J. & van Straaten, H. W. M. Homocysteine interference in neurulation: a chick embryo model. Birth Defects Res. A Clin. Mol. Teratol. 67, 421–428 (2003).
Afman, L. A., Blom, H. J., Drittij, M. J., Brouns, M. R. & van Straaten, H. W. M. Inhibition of transmethylation disturbs neurulation in chick embryos. Brain Res. Dev. Brain Res. 158, 59–65 (2005).
Coelho, C. N. & Klein, N. W. Methionine and neural tube closure in cultured rat embryos: morphological and biochemical analyses. Teratology 42, 437–451 (1990).
Vanaerts, L. A. et al. Prevention of neural tube defects by and toxicity of L-homocysteine in cultured post-implantation rat embryos. Teratology 50, 348–360 (1994).
Bennett, G. D. et al. Failure of homocysteine to induce neural tube defects in a mouse model. Birth Defects Res. B Dev. Reprod. Toxicol. 77, 89–94 (2006).
Greene, N. D., Dunlevy, L. E. & Copp, A. J. Homocysteine is embryotoxic but does not cause neural tube defects in mouse embryos. Anat. Embryol. (Berl.) 206, 185–191 (2003).
Robien, K. & Ulrich, C. M. 5,10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk: a HuGE minireview. Am. J. Epidemiol. 157, 571–582 (2003).
Acknowledgements
We gratefully acknowledge I. van der Linden for her critical comments and valuable support. Our work is supported by grants from the Princess Beatrix Fund and the National Institutes of Health (National Institute of Neurological Disorders and Stroke).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary information S1 (box)
Meta-analysis of MTHFR 677 C>T as risk factor for neural tube defects in mothers and their offspring (PDF 433 kb)
Supplementary information S2 (movie)
Normal neurulation of chicken embryos. (WMV 2591 kb)
Embryos were cultured in a Petri dish at 39°C starting with somite stage of about four and developing until about somite stage nine. Digital images were recorded using a video camera.
Supplementary information S3 (movie)
Inhibition of neurulation by homocysteine. (WMV 2552 kb)
Shows how homocysteine administration hampers normal neurulation, as shown by the widening of the anterior neuropore. Also the closure of the rhombencephalic neuropore is reduced. Control experiments with the same concentrations of leucine and cysteine did not significantly affect neurulation (data not shown).
Related links
Glossary
- Anencephaly
-
A neural tube defect that occurs when there is a failure of neurulation, in which the neural folds do not fuse at the cranial end of the developing embryo. In these infants, most or all of the brain tissue is missing.
- Spina bifida
-
A posterior neural tube defect that is caused by the failure of the neural tube to fuse at the caudal end. Infants with spina bifida can have an open lesion on their spine, where significant damage to the nerves and spinal cord has occurred, or the lesion can be closed.
- Neural plate
-
Neural epithelial cells that form in the early embryo after neuronal induction and give rise to the nervous system.
- Neural crest
-
Groups of cells that migrate from the neural tube to the periphery, where they give rise to a wide variety of cell types.
- Biomarker
-
A characteristic that is objectively measured and evaluated as an indicator of normal biological or pathogenic processes, or pharmacological responses to a therapeutic intervention.
- Single nucleotide polymorphism
-
(SNP). A specific location in a DNA sequence at which different people can have a different DNA base. Differences in a single base could change the protein sequence, leading to disease (for example, sickle-cell disease), or have no known consequences.
- Somites
-
Paired blocks of mesoderm cells along the vertebrate body axis that form during early vertebrate development and differentiate into dermal skin, bone and muscle.
Rights and permissions
About this article
Cite this article
Blom, H., Shaw, G., den Heijer, M. et al. Neural tube defects and folate: case far from closed. Nat Rev Neurosci 7, 724–731 (2006). https://doi.org/10.1038/nrn1986
Issue Date:
DOI: https://doi.org/10.1038/nrn1986
This article is cited by
-
Cdk12 maintains the integrity of adult axons by suppressing actin remodeling
Cell Death Discovery (2023)
-
Time-lapse mechanical imaging of neural tube closure in live embryo using Brillouin microscopy
Scientific Reports (2023)
-
Associations between prenatal exposure to cadmium and lead with neural tube defect risks are modified by single-nucleotide polymorphisms of fetal MTHFR and SOD2: a case–control study
Environmental Health (2021)
-
A new foe in folate metabolism
Nature Metabolism (2021)
-
Association between rare variants in specific functional pathways and human neural tube defects multiple subphenotypes
Neural Development (2020)